Curevo Vaccine logo

Curevo Vaccine

A clinical-stage biotech company developing amezosvatein, a vaccine for shingles and chickenpox.

44 employees · est. 2017 · Bothell, United States

VS
TechnoVax, Inc. logo

TechnoVax, Inc.

5 employees · est. 2003 · United States

TechnoVax, Inc. is the older company (2017 vs 2003); Curevo Vaccine is the larger of the two.

Side-by-Side Comparison

Curevo Vaccine TechnoVax, Inc.
Founded
2017 2003 older
Headquarters
Bothell, United States United States
Employees
44 larger 5
Industry
Biopharma, Biotechnology, Health Care Health Care
Funding Stage
Acquired Equity Crowdfunding
Total Funding
$196.00M Not tracked yet
Funding Rounds
4 1
Services
Development of next-generation non-mRNA vaccines, Clinical trials for vaccine efficacy and safety, Comparative studies with existing vaccines, Improving tolerability and accessibility of vaccines Not tracked yet
Target Customers
Individuals susceptible to shingles and chickenpox, Immunocompromised patients, particularly children, Healthcare providers and institutions, Global health organizations and vaccine distributors Not tracked yet
Taxonomy
Biotech, Vaccine Development, Clinical-Stage Biotech, Amezosvatein, Herpes Zoster Vaccine, Chickenpox Vaccine, Shingles Vaccine, Varicella Zoster Virus, Adjuvanted Subunit Vaccine, Immunology, Drug Development, Reactogenicity Improvement, Public Health, Infectious Disease, Clinical Trials Vaccine Development, Virus-Like Particles, Respiratory Diseases, Hemorrhagic Fevers, Immunodeficiency, Cancer Vaccines, Universal Flu Vaccine, Inhaled Powder Flu Vaccine, RSV Vaccine, Strategic Partnerships, Funding, Clinical-stage Biotechnology, Tarrytown, NY, Non-dilutive Funding
Website
curevovaccine.com technovax.com
Curevo Vaccine logo

About Curevo Vaccine

Curevo Vaccine, founded in 2017, is a clinical-stage biotech company based in the United States. Specializing in the development of vaccines for varicella and herpes zoster, the company is advancing its flagship product, Amezosvatein (CRV-101), a non-mRNA, adjuvanted subunit vaccine aimed at prevent...

TechnoVax, Inc. logo

About TechnoVax, Inc.

TechnoVax, Inc. is a Tarrytown, NY-based biotechnology company founded in 2003. Specializing in viral vaccine development, the company's mission is to create and advance safe, unique, and novel vaccine technologies with no current alternatives, revolutionizing the way vaccines are developed and admi...

We will tell you when either one moves

BounceWatch watches Curevo Vaccine and TechnoVax, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Curevo Vaccine and TechnoVax, Inc. — by email.

Frequently Asked Questions

Curevo Vaccine — A clinical-stage biotech company developing amezosvatein, a vaccine for shingles and chickenpox.. TechnoVax, Inc.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Curevo Vaccine has raised $196.00M while TechnoVax, Inc. has raised undisclosed funding.
Curevo Vaccine and TechnoVax, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Curevo Vaccine with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Curevo Vaccine on 11 Mar 2026, and TechnoVax, Inc. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy